Earnings
Jazz Says Rival Lung Cancer Drug Will Be A 2027 Headwind For Zepzelca, Even As It Raises 2026 Outlook
Jazz lifted its 2026 revenue range to $4.775 billion to $4.85 billion while flagging a competitor to its small cell lung cancer drug.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Jazz lifted its 2026 revenue range to $4.775 billion to $4.85 billion while flagging a competitor to its small cell lung cancer drug.
Earnings
The CFO blamed order timing, not patient demand, and said Middle East conflict is straining customer cash flow.
Earnings
The CFO blamed the Middle East, where third-quarter revenue fell 30%, and management held back 2027 growth guidance.
Earnings
The healthcare REIT reported $0.39 normalized FFO per share and set 2026 guidance of $1.540 to $1.550.
Earnings
Eric Dube said switching away from Filspari has not changed, as third-quarter IgAN patient starts slipped from the second quarter.
Earnings
The digital joint-and-muscle care company swung to an operating profit and lifted its 2026 revenue outlook to $879 million to $881 million.
SEC Filings
The activist fund, which holds about 9.6% of Vail Resorts, urges a vote for Robert Chapek and M. Ashton Hudson on the BLUE card.
Earnings
CEO Steve Kelley says the plant adds capacity "through 2029 easily," while component shortages are built into the fourth-quarter outlook.
Deals
The senior housing REIT posted a $0.02 per-share loss on heavy depreciation, yet lifted its full-year forecast for FFO as adjusted.
Deals
Lumentum holders get 4.5 Marvell shares each and a 33% stake in the combined company, with Matt Murphy staying CEO.
Earnings
New rates in Kansas, Texas and Oklahoma lifted third-quarter operating income to $77.4 million, and the board declared a $0.68 dividend.
Deals
Every LiveRamp director resigned and every executive officer stepped down as the all-cash merger took effect Monday.